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ABSTRACT
Background: The rise in non-communicable diseases
in developing countries has gained increased attention.
Given that around 80% of deaths related to non-
communicable diseases occur in low- and middle-
income countries, there is a need for local knowledge
to address such problems. Longitudinal studies can
provide valuable information about disease burden of
non-communicable diseases in Latin America to
inform both public health and clinical settings.
Methods: The CRONICAS cohort is a longitudinal
study performed in three Peruvian settings that differ
by degree of urbanisation, level of outdoor and indoor
pollution and altitude. The author sought to enrol an
age- and sex-stratiﬁed random sample of 1000
participants at each site. Study procedures include
questionnaires on socio-demographics and well-
known risk factors for cardiopulmonary disease, blood
draw, anthropometry and body composition, blood
pressure and spirometry before and after
bronchodilators. All participants will be visited at
baseline, at 20 and 40 months. A random sample of
100 households at each site will be assessed for 24 h
particulate matter concentration. Primary outcomes
include prevalence of risk factors for cardiopulmonary
diseases, changes in blood pressure and blood
glucose over time and decline in lung function.
Discussion: There is an urgent need to characterise
the prevalence and burden of non-communicable
diseases in low- and middle-income countries. Peru is
a middle-income country currently undergoing a rapid
epidemiological transition. This longitudinal study will
provide valuable information on cardiopulmonary
outcomes in three different settings and will provide
a platform to address potential interventions that are
locally relevant or applicable to other similar settings in
Latin America.
INTRODUCTION
In recent years, non-communicable diseases
in low- and middle-income countries (LMIC)
have received increasingly more global
attention by scientists and by public health
advocates and policy makers. Several publi-
cations underscore the high burden of
disease associated with non-communicable
diseases
1e22 and its economic impact in
LMIC.
23e25 The topic has even reached to
the higher political agenda at the United
Nations in September 2011.
26
Whole determinants of many non-commu-
nicable diseases in LMIC are likely to be
similar to those in afﬂuent countries, yet
population attributable fractions may differ
due to differences in risk factor distributions.
27
There is urgent need to better characterise
current rates of non-communicable disease
morbidity and mortality in LMIC to properly
assess future projections.
28 Most of the
current approaches to understand non-
communicable disease trends in LMIC
are extrapolations of data obtained from
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ARTICLE SUMMARY
Article focus
- Compare prevalence and risk factors of cardio-
vascular and chronic obstructive pulmonary
disease among three different populations.
- Compare rate of disease progression to hyper-
tension and diabetes from a disease-free baseline
status between populations.
- Compare rate of lung function decline between
populations.
Key messages
- Our longitudinal study will provide valuable
information on cardiopulmonary outcomes in
three different settings and will provide a platform
to address potential interventions that are locally
relevant or applicable to other similar settings in
Latin America.
Strengths and limitations of this study
- The CRONICAS cohort is the ﬁrst longitudinal
study in Peru to assess cardiopulmonary risk
factors among population from different
geographical settings.
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Open Access Protocolhigh-income countries; however, since 80% of deaths
related to non-communicable diseases occur in LMIC,
2
generation of local knowledge to address such problems
is needed. This has been recommended by WHO in its
recent ‘Prioritised Research Agenda for Prevention and
Control of Non-Communicable Diseases’.
29
Peru is a middle-income country where non-commu-
nicable diseases are responsible for 42% of total years of
life lost
30; however, mortality proﬁles are heterogeneous
throughout the country and have rapidly shifted from
a pattern dominated by infectious diseases to one
dominated by non-communicable diseases and injuries
over the last decade.
31 As with other countries, cardio-
vascular disease (CVD) risk factors are strongly associ-
ated with lower socioeconomic status in Peru.
32 33 Peru’s
diverse geography along with unequal societal develop-
ment accounts for different stages of the epidemiolog-
ical transition in different populations.
34 35 In the same
way, there is limited information about the burden of
chronic obstructive pulmonary disease (COPD) in Peru.
The PLATINO Study, which excluded Peru, found that
the prevalence of COPD varied from 8% to 20% in
individuals aged 40 years and older in ﬁve large Latin
American cities, suggesting that COPD poses a consider-
able health burden in Latin America.
36 Smoking was
relatively prevalent (23%e29%) across the ﬁve cities
included in PLATINO.
37 In contrast, in Peru, we have
recently found that overall rates of daily tobacco
smoking are substantially lower than in other Latin
American countries.
38 However, other risk factors
unique to LMIC such as biomass fuel exposure can
contribute equally to the burden of COPD.
39 40
Understanding the effects of rapid urbanisation is one
of the grand challenges concerning chronic non-
communicable diseases.
41 Peru offers a unique oppor-
tunity to assess the impact of geographical variation on
non-communicable diseases.
METHODS
Study design and settings
The CRONICAS cohort is a longitudinal study that
started in September 2010. This study is currently being
performed in three settings in Peru (table 1). Pampas de
San Juan de Miraﬂores is a periurban community located
25 km south of Lima’s city centre, with approximately
60000 people in about 4 km
2, consisting mostly of
Andean immigrants. This area is physically diverse and
has experienced signiﬁcant but unplanned population
growth, with residents living on both low and high
ground. The site in Tumbes is located in the northern
coast of Peru and comprised by a group of communities
with about 20000 people spread over 80 km
2, where the
traditional agricultural landscape has become intermixed
with rapidly growing urban sections. Puno is a city in
southeastern Peru, located on the shore of Lake Titicaca.
With a population of approximately 150000 inhabitants,
many villages surround the urban area. Use of biomass
fuels is highly prevalent in these villages. Houses are
made of adobe, and the majority does not have chimneys,
with small windows kept closed, especially in the winter,
due to the low temperatures at high altitudes.
Study objectives
This study has the following objectives: to compare the
(1) prevalence and risk factors of CVD and COPD, (2)
rate of disease progression to hypertension and diabetes
from a disease-free baseline status and (3) rate of lung
function decline between populations.
Participants and selection criteria
All participants had to be aged 35 years and older, be
a full-time resident in the area and be capable of
understanding procedures and of providing informed
consent. Participants who were pregnant, were cogni-
tively incapable of providing informed consent or
responding to a questionnaire, had any physical
disability that would prevent measurements of anthro-
pometrics and blood pressure and had active pulmonary
tuberculosis were excluded. We enrolled only one
participant per household.
Fieldwork personnel selection and training
Fieldwork personnel were trained in a course including
modules on participant selection, human subjects
protection and ethics, informed consent procedures,
interviewing, clinical assessment and coding. The
modules included formal lectures and demonstrations.
Fieldworkers received a copy of an Interviewer’s Manual.
A team of approximately 30 ﬁeld interviewers (10 per
site) was selected. Additionally, a coordinator for each
site was trained in this course. Thus, ﬁeld personnel and
coordinators were capable of conducting interviews and
performing clinical assessments.
Sampling method
We identiﬁed a sex- and age-stratiﬁed random sample
(35e44, 45e54, 55e64, $65 years of age) of potentially
Table 1 Characteristics of the CRONICAS Study settings
Setting Degree of urbanisation Use of biomass fuels
Outdoor
air pollution Altitude
Lima Highly urbanised Rare High Sea level
Tumbes Semi-urban Highly prevalent Low Sea level
Puno, urban Urban Rare Low 3825 m above sea level
Puno, rural Rural Highly prevalent Low 3825 m above sea level
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The CRONICAS cohort protocoleligible subjects. We aimed to enrol 1000 subjects at each
location. In Puno, we stratiﬁed recruitment to include
500 participants each from the urban and rural settings.
Timeline: enrolment, baseline and follow-up visits
Enrolment and baseline data collection started in
September 2010. Follow-up visits will begin in February
2012 and an additional evaluation is planned to start in
June 2013.
At baseline, ﬁeldworkers visited households to contact
potential participants, verify inclusion and exclusion
criteria, invite them to the study, read consent forms,
apply questionnaires to participants and make an initial
appointment for clinical evaluation. If potential partici-
pant was not found after three visits, a subject from the
same age and sex group was randomly selected for
replacement. The team had the responsibility to
complete all clinical measurements and laboratory blood
samples following standardised protocols. Recruitment
of participants continued until the age- and sex-speciﬁc
sample size was reached.
Follow-up visits will be conducted at 20 and 40 months
from enrolment. Sub-sections of the questionnaire as
well as anthropometry, blood pressure and spirometry
will be performed in all three visits. Blood sample
collection will be undertaken only at baseline and at
40 months.
Study procedures
Questionnaires, informed consents, clinical forms and
blood samples were labelled using alphanumeric codes
to identify the site and participant.
Questionnaires
After informed consent was obtained, participants
responded to a face-to-face questionnaire applied by
a trained community health worker using paper-based
formats. Data collected included several factors poten-
tially associated with CVD and COPD, such as age, sex,
years of education and other socioeconomic variables,
smoking and alcohol habits, cardiovascular and respira-
tory symptoms, biomass fuel use and physical activity
patterns. We used a modiﬁed version of WHO’s
STEP approach questionnaire for surveillance of
non-communicable disease.
42 Detailed information
regarding sections and topics of the questionnaire is in
table 2. In addition to the detailed survey, a rejection
questionnaire comprising relevant questions to assure
comparability between participants and non-responders
was also applied to those who refuse to participate.
Phlebotomy and laboratory analyses
A trained technician explained procedures for sample
collection and then participants were asked to provide
venous blood sample for speciﬁc tests (see table 3)i n
fasting conditions, at least 8 but <12 h. New appoint-
ments were scheduled if the fasting period was not
appropriate. A total of 13.5 ml of blood were collected.
Plasma glucose was measured using an enzymatic
colorimetric method (GOD-PAP; Modular P-E/Roche-
Cobas, Grenzach-Whylen, Germany), serum insulin
using electrochemiluminescence (Modular P-E/Roche-
Cobas), highly sensitive C reactive protein using Latex
(Tina-quant CRP-HS Roche/Hitachi analyzer, Indian-
apolis, IN, USA) and haemoglobin A1C using high-
performance liquid chromatography (D10, BioRad,
Munich, Germany), which is traceable to the Diabetes
Control and Complications Trial reference study as
certiﬁed by the National Glycohemoglobin Stand-
ardisation Program. All samples were analysed in a single
facility, and, for quality assurance, the quality of assays
was checked with regular external standards and internal
duplicate assays and monitored by BioRad (http://www.
Table 2 Sections and topics of the questionnaire in the
CRONICAS Study
Type of data Components
Demographic
assessment form:
e Place and date
e Language and informed consents
e Contact information
Socioeconomic
assessment form:
e Demographic information
e Family and expenses
e Household information
e Biomass fuel use
Lifestyle
assessment form:
e Short version of food frequency
questionnaire
e Salt consumption
e Dietary behaviour questionnaire
e Tobacco use and smoking
e Alcohol use
e Self-perception about
health and obesity
e Physical activity
Neighbourhood
walkability form:
e Stores and facilities in the
neighbourhood
e Crime and trafﬁc safety
e Neighbourhood cohesion
e Support
Mental health form: e Depressive symptoms
e Anxiety
Migration
assessment form:
e Migration
e Language use
Treatment
assessment form:
e Cardiovascular medication
e Pulmonary medication
Cardiovascular form: e Personal and familial history
e Stress chest pain
e Intermittent claudication
Respiratory
symptoms form:
e Respiratory symptoms
e Sleep disorders
e Snoring and apnoea
Biomass
exposure form:
e Cooking
e Type of cook stoves
e Use of cook stoves
e Biomass fuel use
Clinical
examination:
e Anthropometric assessment form
e Blood pressure assessment form
e Anklee brachial index form
e Spirometry test form
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detailed in ﬁgure 1.
Clinical assessment
We measured standing and sitting height, waist and hip
circumference in triplicate using standardised tech-
niques, heart rate, systolic and diastolic blood pressure
were in triplicate using an automatic monitor OMRON
HEM-780, previously validated for adult population.
43
Ankleebrachial index, a marker of subclinical athero-
sclerosis that predicts the risk of future vascular events,
44
was also measured using the same device. We measured
weight and bioelectrical impedance using the TBF-300A
body composition analyzer (TANITA Corporation,
Tokyo, Japan). Measurements were carried out
according to manufacturer’s speciﬁcations.
Spirometry
We measured lung function using the Easy-On-PC
spirometer (ndd, Zurich, Switzerland; http://www.ndd.
ch). This device uses a ﬂow metre that is not affected by
changes in barometric pressure and therefore indepen-
dent of gas density and suitable for use at high altitudes.
We trained technicians to comply with the joint Euro-
pean Respiratory Society and American Thoracic Society
guidelines.
45 After training, three of the most skilful
technicians were selected to perform procedures. In
addition, we had a centralised quality control system in
which all tests were graded according to standard
guidelines
46 to ensure that data collected is of highest
quality. Regular calibration checks were performed. We
also provided feedback to ﬁeldworkers regarding
spirometry activities. We recorded forced vital capacity
(FVC), forced expiratory volume in one second (FEV1)
as well as store individual ﬂowevolume curves for
Table 3 Information about biological tests and sample
type
Test Units Sample type
Haemoglobin g/dl Whole blood
Glycated haemoglobin % Whole blood
Fasting glucose mg/dl Plasma with
Na ﬂuoride
Insulin mU/ml Serum
Total cholesterol mg/dl Serum
HDL cholesterol mg/dl Serum
LDL cholesterol* mg/dl Serum
Triglycerides mg/dl Serum
C reactive protein (HS) mg/l Serum
*Calculated using Friedewald equation. In individuals with
triglycerides >400 mg/dl, LDL was measured in serum.
HDL, high-density lipoprotein; HS, high sensitive; LDL, low-density
lipoprotein.
Figure 1 Flow chart of biological
samples processing at laboratory.
– –
–
C reactive
–20°C
–70°C –70°C
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patients underwent bronchodilator-response testing. We
administered two puffs from a salbutamol inhaler
(100 mcg/puff) via a spacer and repeated spirometry
10e15 min later (a generic salbutamol inhaler was used
for this project).
We did not perform spirometry to any subject who had
surgery of heart, chest, lungs or eyes in the past
3 months, or heart attack in the past 3 months, and
a blood pressure greater than 180 (systolic) or 100
(diastolic). We did not use bronchodilators in partici-
pants with a heart rate >120 beats for minute. We
rescheduled spirometry at a later date for participants
who reported having a respiratory infection in the last
2 weeks, who had used a short-term bronchodilators in
the last 4 h or a long-term bronchodilators in the last
12 h or who had smoked in the last hour.
Measures of indoor air pollution
In the second round of assessments, we plan to measure
particulate matter (PM) in a random sample of 10% of
households (100 per site) by placing PM monitors in the
kitchen area. Average PM concentrations will be
measured with the DataRAM pDR-1000 (Thermo Fisher
Scientiﬁc, Waltham, Massachusetts, USA). We expect to
collect PM data over a 48 h period. We will also assess
aspects of household ventilation by measuring size of
room and any windows or doors, as well as noting their
state (open or closed) and the location of the kitchen
and proximity to the living space. We will also record
whether there is a fan in the room and if it was used
during the 48 h of data collection.
Study outcomes
The primary outcomes for the baseline assessment are
prevalence of major risk factors for cardiopulmonary
diseases. The primary outcomes for the follow-up
include longitudinal changes in blood pressure, blood
glucose and lung function over 40 months. We will also
able to assess traditional risk factors for CVD and COPD
in all follow-up visits.
Hypertension rates will be calculated using the average
of the second and third blood pressure measures.
Hypertension will be deﬁned as the systolic blood pressure
$140 mm Hg, and/or diastolic blood pressure
$90 mm Hg, and/or self-report of current use of anti-
hypertensive drugs.
47 Diabetes mellitus will be deﬁned as
a fasting glucose $126 mg/dl (or $7 mmol/l) or self-
report of physician diagnosis and currently receiving
antidiabetic medication.
48 As local references do not exist,
we will deﬁne COPD as the presence of airﬂow limitation
characterised by FEV1/FVC <70%.
49 50 We will deﬁne
reversibility as an improvement of >12% or >200 ml in
baseline FEV1 or FVC in the post-salbutamol assessment.
51
Sample size and power
Calculations for CVD outcomes were derived using
prevalence estimates of hypertension from PERU
MIGRANT Study.
38 52 Prevalence in urban (Lima),
migrant and rural groups was 30%, 13% and 12%,
respectively. With 1000 people in each study site, the
study would have power $80%, at the 5% signiﬁcance
level, to detect a 3% absolute difference in the preva-
lence of progression to hypertension between the sites
over 4 years (ie, 8% will develop hypertension in Lima,
5% in Puno and 2% in Tumbes).
To calculate the sample size for determining a differ-
ence in prevalence of COPD between site, we assume
a prevalence ranging from 6% in Lima to 12% in
Tumbes or Puno, with 5% signiﬁcance and 90%
power. We estimate a sample size of approximately 509
participants per site.
Sample size calculations for lung function assessment
over time included parameter and variances estimates
from the UPLIFT trial,
53 a 4-year study of tiotropium in
COPD, using the following model:
FEV1ij
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In this model, FEV1 is expressed in millilitres and
height in metres. The outcome is equivalent to a height-
adjusted FEV1. FEV1 is also affected by age, and this
relationship is unlikely to be linear. However, we assume
that the rate of decline over 40 months for each indi-
vidual will be approximately linear. The values tij repre-
sents the jth measurement time for the ith participant.
The bs are the regression parameters, and bi is the
random effects. We used estimates obtained for male
participants given that 75% of trial participants were
male and that these estimates are likely to have the least
amount of variability given the sample size of about 4000
participants. To calculate the sample size needed to
detect a difference in our study from UPLIFT estimates,
we used the following equation:
nnew ¼
SEb1
2

UPLIFT

SEb1
2

new


LUPLIFT
Lnew
2
nUPLIFT;
where nnew is the sample size for our study; nUPLIFT is the
sample size in UPLIFT trial; the SEs are the estimate of
the SE for the expected b1 in our study and in UPLIFT,
respectively and L is the follow-up duration in our study
and in UPLIFT. Since we expect to follow all individuals
for approximately 4 years, our study duration is similar
to that of UPLIFT. We obtained the sex-stratiﬁed esti-
mates from UPLIFT investigators.
53 The SE for our study
can be estimated as:
SEb1

new

¼
db
_
1
Zð1 powerÞ ZðaÞ
;
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h
is the
estimate of annual decline in FEV1 estimated from
UPLIFT, Z(1-power) and Z(a) are the associated power
and conﬁdence level. Therefore, to detect a 50%
change in the rate of decline in FEV1/height
2 between
sites with 5% signiﬁcance and 90% power requires
a total of 332 participants at each site followed longitu-
dinally for 48 months. We assume that the rate of lung
function decline for Tumbes will be similar to that of
Lima. Assuming at 20% loss to follow-up, this would
require approximately 400 participants. Even if we
reduce the overall rate of decline in lung function
by 25%, this would only increase the sample size
requirement to 590 participants. Assuming at 20% loss
to follow-up, this would require approximately 700
participants.
Statistical methodology and analysis
Following double data entry and careful data cleaning
and consistency checking, descriptive statistics using
tabulations and graphical methods will be performed.
Direct standardisation to WHO standard population
54
will be used to calculate age-standardised prevalences by
speciﬁc age groups. Standardised mean differences,
a unit-free comparison technique, will be used to
evaluate the magnitude of difference between risk
factors.
55 56 The analysis will take into account the
stratiﬁed nature of the sample at all stages and the
repeated measures in individuals.
Logistic regression (for binary outcomes) and multi-
variable linear regressions (for continuous normally
distributed outcomes) will be used to assess the rela-
tionship between urbanisation and major cardiovascular
and COPD risk factors. Appropriate longitudinal data
methods will be used for the assessment of disease
progression from baseline disease-free status to disease
at follow-up. Multivariable models will look for risk
factors that explain the relationship, such as blood
pressure or fasting glucose when appropriate, body mass
index, fasting total cholesterol, alcohol consumption,
smoking status, regular exercise, income and other
socioeconomic indicators as well as area of residence,
will be pursued. Multilevel analysis to compare disease
progression for site will be also considered.
Ethical aspects
This protocol and informed consent forms were
approved with respect to scientiﬁc content and compli-
ance with applicable research and human subjects’
regulations. Protocol and consent forms were reviewed
and approved by Institutional Review Boards at Univer-
sidad Peruana Cayetano Heredia and Johns Hopkins
University.
All investigators and personnel in the study have
completed a training course in ethics and human
subjects protection, certiﬁed by the National Institutes of
Health. Informed consents were verbal because of sites
included in this study were semi-urban and rural with
signiﬁcant rates of illiteracy; thus, interviewer signed the
form to document participants’ approval.
DISCUSSION
This work emphasises the need of studies in different
parts of the world, especially in LMIC to understand and
assess non-communicable diseases and their risk factors.
Peru is a very diverse country with different rates of
urbanisation; thus, progression towards non-communi-
cable conditions can vary widely from one geographical
area to another. To our knowledge, two different cohorts
are assessing non-communicable diseases in Latin
America. The ﬁrst one, the ELSA Study, a Brazilian
cohort, has involved ‘white-collar’ volunteers to evaluate
cardiovascular events.
57 The second one, the CESCAS I
Study, has started a cohort of participants focused in
urban settings from Argentina, Chile and Uruguay to
obtain CVD incidence using a multistage probabilistic
sample.
58
The burden of non-communicable in LMIC is only
expected to increase, yet limited data are available in
these settings. Extrapolation of trends using data from
high-income countries, where age proﬁles, risk factors
and body composition differ, is unlikely to provide
reasonable estimates or public health strategies to
decrease disease burden. Generation of local knowledge
to address such problems is needed to measure the
magnitude of the problem, assess risk factors, which
might be completely different from developed countries,
and identify high-risk groups.
59 The CRONICAS cohort
has established a large cardiopulmonary cohort of
adults, who will be followed-up over at least 4 years, with
the possibility of longer term follow-ups and thus estab-
lishing itself as a unique resource arising from one LMIC
in an area of major public health concern.
There are several strengths that distinguish our
study from other large-scale studies in Latin America. On
the cardiovascular side, the assessment of risk using
scores derived from developed countries has shown
limitations in developing societies and may have limited
application in settings like Peru. Determination of non-
communicable disease epidemiology requires context-
speciﬁc evaluation and follow-up of subjects over time,
and this information is not available for Peru. On the
pulmonary side, our study ﬁndings will complement that
of BOLD and PLATINO as we will be able to provide an
evaluation of longitudinal assessments of lung function
across several settings according to degree of urbanisa-
tion, levels of outdoor and indoor air pollution and
altitude. Speciﬁcally, our research will expand on the
knowledge base of the epidemiology of lung function in
LMIC with a high prevalence of biomass fuel exposure.
Moreover, our data can also be used to generate local
references for lung function among healthy, non-
smoking non-biomass fuel-exposed adults, which
currently do not exist for Peru. Most importantly, the
uniqueness of geographical settings, the variety of stages
of urbanisation, the long-term design of the study in an
6 Miranda JJ, Bernabe-Ortiz A, Smeeth L, et al. BMJ Open 2012;2:e000610. doi:10.1136/bmjopen-2011-000610
The CRONICAS cohort protocolLMIC and the integration of cardiovascular- and
pulmonary-related assessments will generate compre-
hensive data that will, in turn, provide important
advances for public health and for the ﬁeld of non-
communicable diseases in LMIC.
In Peru, according to WHO’s 2011 non-communicable
diseases country proﬁle, there is no data regarding
behavioural risk factors, especially in current daily
tobacco smoking and physical inactivity prevalences.
60 In
addition, this report highlights the lack of an integrated
policy programme for CVD, chronic respiratory diseases,
diabetes, cancer, alcohol, tobacco, unhealthy diet,
obesity and physical inactivity.
60 Therefore, reducing the
impact of non-communicable diseases will require alli-
ances between different groups of research beyond
national boundaries. With the support of the National
Heart, Lung, and Blood Institute, we have the opportu-
nity to establish initial steps towards an appropriate
surveillance system for chronic diseases in Peru. The
information gathered in this protocol will provide
a strong platform to address potential interventions that
are locally relevant and that could be applicable to other
settings in Latin America, other LMIC and eventually
potentially relevant for Latin population in the USA.
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APPENDIX 1
CRONICAS cohort study group (members listed in
alphabetical order)
Cardiovascular Disease: Antonio Bernabe ´-Ortiz, Juan P Casas,
George Davey Smith, Shah Ebrahim, Rau ´l Gamboa, He ´ctor H Garcı ´a,
Robert H Gilman, Luis Huicho, Germa ´nM a ´laga, J Jaime Miranda,
Vı ´ctor M Montori, Liam Smeeth; Chronic Obstructive Pulmonary
Disease: William Checkley, Gregory B Diette, Robert H Gilman, Luis
Huicho, Fabiola Leo ´n-Velarde, Marı ´a Rivera, Robert A Wise; Training
& Capacity Building: William Checkley, He ´ctor H Garcı ´a, Robert H
Gilman, J Jaime Miranda, Katherine Sacksteder.
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